1.
Monoclonal Antibodies and Immunoassay for Medical Plant-Derived Natural Products: A Review.
Yan, X, Zhao, Y, Zhang, Y, Qu, H
Molecules (Basel, Switzerland). 2017;(3)
Abstract
Owing to the widespread application value, monoclonal antibodies (MAbs) have become a tool of increasing importance in modern bioscience research since their emergence. Recently, some researchers have focused on the production of MAbs against medical plant-derived natural products (MPNP), the secondary metabolites of medical plants. At the same time, various immunoassay methods were established on the basis of these MPNP MAbs, and then rapidly developed into a novel technique for medical plant and phytomedicine research in the area of quality control, pharmacological analysis, drug discovery, and so on. Dependent on the research works carried out in recent years, this paper aims to provide a comprehensive review of MAbs against MPNP and the application of various immunoassay methods established on the basis of these MAbs, and conclude with a short section on future prospects and research trends in this area.
2.
Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation.
Bian, H, Zheng, JS, Nan, G, Li, R, Chen, C, Hu, CX, Zhang, Y, Sun, B, Wang, XL, Cui, SC, et al
Journal of the National Cancer Institute. 2014;(9)
Abstract
To assess the efficacy of combining radioimmunoconjugate [(131)I] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0-B stage. Patients received either RFA followed by [(131)I] metuximab (n = 62) or RFA alone (n = 65). The primary outcome was overall tumor recurrence. Statistical tests were two-sided. The one- and two-year recurrence rates in the combination group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (P = .03). The RFA-[(131)I] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuximab target (ie, CD147)-positive subpopulation (P = .007). [(131)I] metuximab may yield prevention of tumor recurrence after RFA.
3.
Anti-cAngptl4 Ab-conjugated N-TiO(2) /NaYF(4) :Yb,Tm nanocomposite for near infrared-triggered drug release and enhanced targeted cancer cell ablation.
Xu, QC, Zhang, Y, Tan, MJ, Liu, Y, Yuan, S, Choong, C, Tan, NS, Tan, TT
Advanced healthcare materials. 2012;(4):470-4
Abstract
Nanomedicine: NIR-active N-TiO(2) /NaYF(4) :Yb,Tm nanocomposites (NCs) were synthesized for the first time and its potential applications in drug release and targeted cancer cell ablation are explored. Upon 980 nm laser irradiation, the anti-cAngptl4 Ab-conjugated N-TiO(2) /NaYF(4) :Yb,Tm NCs shows a significant increase in apoptotic A-5RT3 cells when compared with that of the unconjugated NCs. The mechanisms for NIR-induced photocatalysis, drug release and targeted cancer cell killing are proposed.